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TIE aim ofthe present studywas to compare serum levels
of soluble forms of interleukin-2 receptor, CD4 and CD8,
releasedby lymphocytes during activation ofthe immune
system, in patients with histologically verified chronic
active hepatitis associated to hepatitis C virus infection,
with those in healthy subjects. Significantly higher levels
of soluble IL-2R and soluble CD8 were found in patients
with chronic active hepatitis compared with controls. In
contrast no difference was found for soluble CD4 values
in the two groups. No correlations were found for both
sIL-2R and sCD8 and these two molecules with other
parameters of liver function. These results indicate that
in these patients there is a general activation of the im-
mune system, but the lack ofcorrelation with parameters
of liver function strengthens the suggestion that this
activation does not play a role in the pathogenesis of
chronic type C hepatitis.
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Introduction
During activation, lymphocytes secrete glyco-
proteins related to their surface proteins, including
interleukin-2 receptor (IL-2R), CD4 and CD8 soluble
forms. These glycoproteins are found in relatively
large amounts in the circulation and it is possible to
obtain normal ranges for normal persons, with upper
limits. This allows the detection of states of increased
production of soluble interleukin-2 receptor (sIL-2R),
soluble CD4 and CD8 (sCD4 and sCD8) correspond-
ing to increased activation of the immune system.
Increased levels of a soluble form of these
glycoproteins have been observed in the serum of
patients with malignant, autoimmune and allergic
disorders, as well as in subjects affected by systemic
infectious diseases or undergoing allograft rejection.
Thus, the release of these soluble molecules appears
to be a characteristic marker of lymphocyte or
mononuclear cell (MNC) activation. In infectious
diseases the elevation of serum soluble molecules is
likely to indicate immune system activation in re-
sponse to antigenic challenge by infectious agents.
Particularly, levels of sCD8 are increased in diseases
where there is a prominent role of cytotoxic T cells,
such as viral infection.1-
It has been suggested that hepatitis C virus (HCV)
is directly cytopathic and liver cell damage in HCV
infection is not mediated by cytotoxic T cells directed
against the viral determinants expressed on the in-
fected hepatocytes, Nevertheless, several results sug-
gest that in these patients there may be various
impairments of immune functions, but no relation-
ship has been demonstrated between the impairment
and the natural history of the disease.7-1 In the
present paper, to gain insight into the significance of
these impairments, serum levels of slL-2R, sCD4 and
sCD8 in patients with chronic HCV infection have
been studied.
Materials and Methods
Samplepopulation: A total of 84 subjects was studied;
33 were patients with histologically verified chronic
type C hepatitis (twelve females and 21 males, range
40-65 years). No other aetiological factors were asso-
ciated, such as positivity for HBc antibodies,
autoimmune markers, alcohol consumption,
Wilson’s disease, zl anti-trypsin deficiency. Transfu-
sion or previous surgery were the main risk factors
in most patients.
The remainder consisted of 51 healthy adults (26
females and 25 males, range 20-64 years). None of
these subjects had a history of prolonged disease and
none was ill or taking any drug at the time of the
study. Blood was taken from all the subjects during
the same period of time (6 months). The sera were
stored at-70C until assay.
Laboratory tests: Serological testing for anti-HCV was
performed using a second generation commercial
ELISA (Ortho Diagnostic Systems, Raritan, NJ, USA)
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according to the manufacturer’s instructions. Anti-
HCV reactive samples were confirmed using a sec-
ond generation anti-HCV recombinant immunoblot
assay (RIBA II, Chiron Corporation, Emeryville, CA,
USA). In this test the nitrocellulose strip contains four
viral antigens, three of the non-structural regions
(5-1-1; C-100; C-33c) and one structural peptide
(c 22-3). Patients were defined positive when speci-
mens reacted with at least two of the bands, indeter-
minate when specimens reacted with one band only
and negative when there was no reaction. Hepatitis
B core antigens were tested using the Abbott RIA kit
(Abbott Laboratories, N. Chicago, IL, USA).
The main biochemical parameters of liver function
were assayed using commercially available kits.
Liver biopsy specimens were obtained
percutaneously with a Menghini needle and CAH
was defined according to the criteria of De Groote
et al.
11
Quanta’cation of soluble molecules: An enzyme
immunoassay test has been used to quantify sIL-2R,
sCD4 and sCD8. The assays were performed with
commercially available kits purchased from Cellfree
(T Cell Sciences, Inc., Cambridge, MA, USA). All tests
were performed according to the manufacturer’s in-
structions. Detection limits in the authors’ laboratory
for sIL-2R, sCD4 and sCD8 were 50 U/ml, 12 U/ml
and 50 U/ml, respectively.
Statistical analysis: All data are expressed as
means + S.D. Correlations were calculated by linear
regression. The values for the different groups were
compared using Student’s t-test.
Results
Patients with chronic type C hepatitis have signifi-
cantly higher levels of sIL-2R than do normal controls
(Table 1). For the soluble forms of CD4 and CD8,
sCD8 levels were significantly increased in patients,
whereas for sCD4 no significant difference was ob-
served between the two groups, as shown in Table
1. It is interesting to note that in spite of the simul-
taneous increase of both slL-2R and sCD8, no corre-
lation was demonstrated between the levels of these
two molecules (r= 0.25; p= n.s.). In addition, no
significant correlation between serum levels of slL-2R
Table 1. Serum levels (mean _+ S.D.) of soluble IL-2R, CD4 and
CD8 in 51 normal controls and 33 chronic type C hepatitis patients
Serum levels of glycoprotein
Glycoprotein Healthy subjects Patients
slL-2R 497 +_ 786 1511 + 972
sCD4 30 + 15 34 + 19
sCD8 389 + 147" 941 + 384
p values for: a vs. b, 2.77-6; c vs. d, 1.82-1’; e vs. f, n.s.
Table 2. Serum levels (mean _+ S.D.) of soluble IL-2R and CD8 in
22 patients at day 0 after 6 months
Serum levels of glycoprotein
Glycoprotein At day 0 After 6 months
slL-2R 1233 _+ 506 1275 + 473
sCD8 900 + 357 879 + 268
p values for: a vs. b, n.s.; c vs. d, n.s.
or sCD8 and those of alanine amino transferase (ALT)
or other markers of liver disease was observed (data
not shown).
In a small number of patients, available for a
second observation after 6 months, the sera showed
mean levels of these soluble molecules almost iden-
tical to those of the first observation (Table 2).
Discussion
The present results demonstrate that in patients
affected by chronic type C hepatitis there is a signifi-
cant increase of slL-2R and sCD8 but not of sCD4.
This increase is present during the whole course of
the disease as demonstrated by the fact that a second
assay of these soluble molecules on the sera of the
same patients 6 months later showed no significant
changes.
Serum sIL-2R has been measured in patients af-
fected by several liver diseases. All patients with
acute type B hepatitis presented levels significantly
higher than that of normal controls or of patients
with chronic type B hepatitis. Serial follow-up
showed that serum levels of slL-2R tended to return
to normal 2-4 months after onset of acute hepatitis
together with the ALT normalization. Patients with
chronic type B hepatitis also had significantly higher
levels of sIL-2R that varied considerably with liver
flogosis, i.e. significantly lower levels were detected
in patients with chronic infection who had no evi-
dence of active liver disease. In chronic infection, in
response to therapy with prednisone and/or inter-
feron, serum sIL-2R fell significantly and a significant
correlation between serum sIL-2R and ALT levels has
been observed. High slL-2R levels have also been
observed during hepatitis A infection, while lower
values have been seen during acute hepatitis C infec-
tion.
Soluble IL-2R has also been measured in the serum
of patients with liver cirrhosis, patients with obstruc-
tive jaundice and patients with alcoholic liver disease
without evidence of cirrhosis. In patients with cirrho-
sis and obstructive jaundice sIL-2R was significantly
increased compared with healthy subjects. No differ-
ence was found between patients with cirrhosis due
to alcohol abuse and chronic hepatitis B. 1-12 In ob-
structive jaundice, sIL-2R correlated with alkaline
phosphatase as a marker of cholestasis.3
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Concerning serum sCD8 levels, this glycoprotein
was increased in patients with cirrhosis but not in
patients with obstructive jaundice, compared with
healthy subjects and patients with unrelated dis-
eases. No difference was found between patients
with cirrhosis due to alcohol abuse and chronic
hepatitis B. 12-15
On the whole these data show that in spite of the
apparent well-known depressed cellular immune
response both in liver cirrhosis and obstructive jaun-
dice14’15 there is a general activation of the immune
system. The same is true for type C chronic hepatitis
(present results). However, in other liver diseases
there may be a correlation between the increase of
soluble factors and the signs of liver impairment (for
instance in chronic type B hepatitis there is a strong
correlation between serum sIL-2R levels and ALT,
and in jaundice there is a correlation between sIL-2R
levels and alkaline phosphatase). This does not oc-
cur in CAH. The lack of correlation strengthens the
suggestion that the activation of the immune system
does not play a role in the pathogenesis of chronic
type C hepatitis that is due almost exclusively to a
cytopathic effect of virus.7-1
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